Tarcidomgen Kimleucel

N/A

Report date: 2024/09/25 20:00:35

Base Information

Drug NameTarcidomgen Kimleucel

Drug Alias Nameautologous anti-CD19 CAR T cells therapy(FamiCordTx)FCTX-CL19-1

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacementsB-lymphocyte antigen CD19 modulators

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsLymphoma, Mantle-CellLymphoma, B-CellPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryPoland

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesFamiCordTx SA

China Registration ClassN/A

Develop Information

Active CompaniesFamiCordTx SA

Inactive CompaniesN/A

Active IndicationsLymphoma, Mantle-CellLymphoma, B-CellPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A